Truist Financial Issues Positive Forecast for OrthoPediatrics (NASDAQ:KIDS) Stock Price

OrthoPediatrics (NASDAQ:KIDS) had its target price increased by Truist Financial from $17.00 to $20.00 in a research report released on Thursday morning,Benzinga reports. The brokerage currently has a hold rating on the stock.

A number of other equities analysts have also weighed in on KIDS. Canaccord Genuity Group set a $25.00 price objective on OrthoPediatrics in a research note on Friday, April 24th. TD Cowen reissued a “buy” rating on shares of OrthoPediatrics in a report on Monday, June 15th. Weiss Ratings reissued a “sell (e+)” rating on shares of OrthoPediatrics in a report on Tuesday, April 21st. Finally, BTIG Research reaffirmed a “buy” rating and set a $24.00 price objective on shares of OrthoPediatrics in a report on Friday, May 1st. Nine analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $24.78.

OrthoPediatrics Stock Up 3.3%

KIDS opened at $20.38 on Thursday. The company has a debt-to-equity ratio of 0.29, a quick ratio of 2.37 and a current ratio of 5.21. OrthoPediatrics has a fifty-two week low of $14.42 and a fifty-two week high of $23.70. The firm’s fifty day moving average is $18.63 and its 200 day moving average is $17.69. The stock has a market cap of $523.36 million, a price-to-earnings ratio of -12.13 and a beta of 0.99.

OrthoPediatrics (NASDAQ:KIDS) last issued its quarterly earnings results on Thursday, April 30th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.04. The business had revenue of $59.36 million during the quarter, compared to analyst estimates of $58.28 million. OrthoPediatrics had a negative return on equity of 7.01% and a negative net margin of 16.31%. On average, sell-side analysts forecast that OrthoPediatrics will post -1.13 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of KIDS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of OrthoPediatrics by 6.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,995 shares of the company’s stock valued at $246,000 after purchasing an additional 645 shares in the last quarter. Russell Investments Group Ltd. raised its stake in OrthoPediatrics by 433.1% during the third quarter. Russell Investments Group Ltd. now owns 1,402 shares of the company’s stock valued at $26,000 after purchasing an additional 1,139 shares in the last quarter. BNP Paribas Financial Markets raised its stake in OrthoPediatrics by 60.2% during the third quarter. BNP Paribas Financial Markets now owns 3,288 shares of the company’s stock valued at $61,000 after purchasing an additional 1,235 shares in the last quarter. Northwestern Mutual Wealth Management Co. lifted its position in OrthoPediatrics by 5,226.5% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 2,610 shares of the company’s stock valued at $46,000 after purchasing an additional 2,561 shares during the last quarter. Finally, Barclays PLC lifted its position in OrthoPediatrics by 10.7% during the fourth quarter. Barclays PLC now owns 26,405 shares of the company’s stock valued at $469,000 after purchasing an additional 2,561 shares during the last quarter. 69.05% of the stock is currently owned by institutional investors.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.